| 168.74 -1 (-0.59%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 204.17 | 1-year : | 238.47 |
| Resists | First : | 174.8 | Second : | 204.17 |
| Pivot price | 162.74  |
|||
| Supports | First : | 160.88 | Second : | 152.27 |
| MAs | MA(5) : | 169.55 |
MA(20) : | 161.76 |
| MA(100) : | 164.21 |
MA(250) : | 133.59 |
|
| MACD | MACD : | 0.1 |
Signal : | -1.7 |
| %K %D | K(14,3) : | 74.1  |
D(3) : | 78.2 |
| RSI | RSI(14): 54.4 |
|||
| 52-week | High : | 191.5 | Low : | 86.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AXSM ] has closed below upper band by 21.5%. Bollinger Bands are 0.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 169.49 - 170.35 | 170.35 - 171.05 |
| Low: | 163.2 - 164.1 | 164.1 - 164.84 |
| Close: | 167.4 - 168.83 | 168.83 - 170.01 |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Mon, 06 Apr 2026
Axsome Therapeutics (AXSM) Q2 2024 earnings summary - Quartr
Sat, 04 Apr 2026
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Balipodect Licensing Deal From Takeda - Sahm
Sat, 04 Apr 2026
Element Squared LLC Invests $1.48 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Wed, 01 Apr 2026
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda - Benzinga
Wed, 01 Apr 2026
Axsome Therapeutics (NASDAQ: AXSM) secures global rights to balipodect - Stock Titan
Wed, 01 Apr 2026
Axsome adds a schizophrenia drug candidate, targets 2026 Phase 3 prep - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 15.4 (%) |
| Held by Institutions | 75.8 (%) |
| Shares Short | 2,760 (K) |
| Shares Short P.Month | 2,710 (K) |
| EPS | -3.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.74 |
| Profit Margin | -28.7 % |
| Operating Margin | -18.4 % |
| Return on Assets (ttm) | -16.9 % |
| Return on Equity (ttm) | -252.2 % |
| Qtrly Rev. Growth | 65 % |
| Gross Profit (p.s.) | 11.55 |
| Sales Per Share | 12.48 |
| EBITDA (p.s.) | -3.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -93 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -45.98 |
| PEG Ratio | 0 |
| Price to Book value | 96.97 |
| Price to Sales | 13.51 |
| Price to Cash Flow | -92.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|